• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

    2/12/25 4:05:00 PM ET
    $TXG
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TXG alert in real time by email

    PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025.

    10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.)

    Recent Updates

    • Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023.
    • In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Genomics, launched the Billion Cells Project, an effort to generate an unprecedented one billion cell dataset to fuel rapid progress in AI model development in biology.
    • Cash and cash equivalents and marketable securities were $393.4 million as of December 31, 2024, an increase of $4.7 million over prior year.

    "In 2024, we launched major new products across all three of our platforms and we made changes to our commercial organization and go-to-market strategy," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "As we kick off 2025, our goal is to take advantage of these changes and deliver consistent execution. Despite the current uncertainty within U.S. academic research, we continue to have strong conviction in the large opportunity ahead."

    Fourth Quarter 2024 Financial Results

    Revenue was $165.0 million for the three months ended December 31, 2024, a 10% decrease from $184.0 million for the corresponding period. 

    Gross margin was 67% for the fourth quarter of 2024, as compared to 63% for the corresponding prior year period. The increase in gross margin was primarily due to change in product mix.

    Operating expenses were $160.8 million for the fourth quarter of 2024, a 6% decrease from $171.0 million for the corresponding prior year period. The decrease was primarily driven by a $19.6 million in-process research and development expense related to an agreement to acquire certain intangible and other assets in the prior year period, partially offset by an increase in outside litigation expenses.

    Operating loss was $49.8 million for the fourth quarter of 2024, as compared to an operating loss of $55.2 million for the corresponding prior year period. Operating loss includes $32.5 million of stock-based compensation for the fourth quarter of 2024, as compared to $38.9 million for the fourth quarter of 2023.

    Net loss was $49.0 million for the fourth quarter of 2024, as compared to a net loss of $49.0 million for the corresponding prior year period.

    Full Year 2024 Financial Results

    Revenue was $610.8 million for the year ended December 31, 2024, a 1% decrease from $618.7 million for 2023.

    Gross margin was 68% for full year 2024, as compared to 66% for 2023. The increase in gross margin was primarily due to change in product mix.

    Operating expenses were $609.0 million for full year 2024, as compared to $674.6 million for 2023, an decrease of 10%. The decrease was primarily driven by a $61.0 million in-process research and development expense related to an agreement to acquire certain intangible and other assets in the prior year period and lower personnel expenses, including stock-based compensation expense, partially offset by higher outside legal expenses.

    Operating loss was $194.6 million for full year 2024, as compared to an operating loss of $265.3 million for 2023. This includes $140.7 million of stock-based compensation for full year 2024, as compared to $167.0 million for full year 2023.

    Net loss was $182.6 million for full year 2024, as compared to a net loss of $255.1 million for 2023.

    Cash and cash equivalents and marketable securities were $393.4 million as of December 31, 2024.

    2025 Financial Guidance 

    10x Genomics expects full year 2025 revenue to be in the range of $610 million to $630 million, representing 0% to 3% growth over full year 2024. At the midpoint, this guidance implies double-digit growth for both Chromium reactions and overall spatial revenue.

    Webcast and Conference Call Information

    10x Genomics will host a conference call to discuss the fourth quarter and full year 2024 financial results, business developments and outlook after market close on Thursday, February 12, 2025 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast of the conference call can be accessed at http://investors.10xgenomics.com. The webcast will be archived and available for replay for at least 45 days after the event.

    About 10x Genomics

    10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn, X (Twitter), Facebook, Bluesky or YouTube.

    Forward Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding 10x Genomics, Inc.'s collaboration with CZI and Ultima Genomics, positioning, product launches, commercial organization restructuring, go-to-market strategy, goals, uncertainty within academic research, commercial opportunity and our financial performance and results of operations, including our expectations regarding revenue and guidance. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time.

    Disclosure Information

    10x Genomics uses filings with the Securities and Exchange Commission, our website (www.10xgenomics.com), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD.

    Contacts

    Investors: [email protected]

    Media: [email protected] 

    10x Genomics, Inc.

    Consolidated Statement of Operations

    (Unaudited)

    (In thousands, except share and per share data)





    Three Months Ended

    December 31,



    Year Ended

    December 31,



    2024



    2023



    2024



    2023

    Revenue (1)

    $         165,021



    $         183,979



    $         610,785



    $         618,727

    Cost of revenue (2)

    54,066



    68,197



    196,303



    209,414

    Gross profit

    110,955



    115,782



    414,482



    409,313

    Operating expenses:















    Research and development (2)

    66,968



    65,267



    264,698



    270,332

    In-process research and development

    —



    19,578



    —



    60,980

    Selling, general and administrative (2)

    93,826



    86,125



    344,343



    343,330

    Total operating expenses

    160,794



    170,970



    609,041



    674,642

    Loss from operations

    (49,839)



    (55,188)



    (194,559)



    (265,329)

    Other income (expense):















    Interest income

    4,026



    4,637



    18,448



    16,906

    Interest expense

    —



    (8)



    (4)



    (33)

    Other income (expense), net

    (2,567)



    3,961



    (1,585)



    (307)

    Total other income

    1,459



    8,590



    16,859



    16,566

    Loss before provision for income taxes

    (48,380)



    (46,598)



    (177,700)



    (248,763)

    Provision for income taxes

    648



    2,354



    4,927



    6,336

    Net loss

    $          (49,028)



    $          (48,952)



    $       (182,627)



    $       (255,099)

















    Net loss per share, basic and diluted

    $              (0.40)



    $              (0.41)



    $              (1.52)



    $              (2.18)

    Weighted-average shares used to compute net loss per share, basic and diluted

    121,596,351



    118,565,724



    120,451,550



    117,165,036





    (1)

    The following table represents revenue by source for the periods indicated (in thousands). Spatial products includes the Company's Visium and Xenium products:

     





    Three Months Ended

    December 31,



    Year Ended

    December 31,





    2024



    2023



    2024



    2023

    Instruments

















    Chromium



    $           10,929



    $           11,150



    $           35,212



    $           47,866

    Spatial



    13,425



    27,248



    57,503



    75,605

    Total instruments revenue



    24,354



    38,398



    92,715



    123,471

    Consumables

















    Chromium



    97,737



    118,144



    372,308



    420,316

    Spatial



    35,795



    22,170



    121,124



    59,237

    Total consumables revenue



    133,532



    140,314



    493,432



    479,553

    Services



    7,135



    5,267



    24,638



    15,703

    Total revenue



    $         165,021



    $         183,979



    $         610,785



    $         618,727

     

    The following table presents revenue by geography based on the location of the customer for the periods indicated (in thousands):







    Three Months Ended

    December 31,



    Year Ended

    December 31,





    2024



    2023



    2024



    2023

    Americas

















    United States



    $           84,285



    $           99,322



    $         334,318



    $         360,091

    Americas (excluding United States)



    2,936



    4,520



    13,447



    13,101

    Total Americas



    87,221



    103,842



    347,765



    373,192

    Europe, Middle East and Africa



    49,828



    50,589



    159,762



    142,276

    Asia-Pacific

















    China



    14,609



    11,748



    57,300



    50,965

    Asia-Pacific (excluding China)



    13,363



    17,800



    45,958



    52,294

    Total Asia-Pacific



    27,972



    29,548



    103,258



    103,259

    Total Revenue



    $         165,021



    $         183,979



    $         610,785



    $         618,727

     

    (2)

    Includes stock-based compensation expense as follows:







    Three Months Ended

    December 31,



    Year Ended

    December 31,

    (in thousands)

    2024



    2023



    2024



    2023

    Cost of revenue

    $           2,221



    $           1,928



    $           8,348



    $           7,068

    Research and development

    15,587



    17,608



    66,315



    72,804

    Selling, general and administrative

    14,731



    19,382



    66,086



    87,078

    Total stock-based compensation expense

    $         32,539



    $         38,918



    $       140,749



    $       166,950

     

    10x Genomics, Inc.

    Consolidated Balance Sheets

    (In thousands, except share and per share data)





    December 31,



    2024



    2023

    Assets







    Current assets:







    Cash and cash equivalents

    $         344,067



    $         359,284

    Marketable securities

    49,335



    29,411

    Accounts receivable, net

    87,862



    114,832

    Inventory

    83,107



    73,706

    Prepaid expenses and other current assets

    20,016



    18,789

    Total current assets

    584,387



    596,022

    Property and equipment, net

    252,648



    279,571

    Operating lease right-of-use assets

    57,290



    65,361

    Goodwill

    4,511



    4,511

    Intangible assets, net

    15,671



    16,616

    Other noncurrent assets

    4,129



    3,062

    Total assets

    $         918,636



    $         965,143

    Liabilities and stockholders' equity







    Current liabilities:







    Accounts payable

    $           12,909



    $           15,738

    Accrued compensation and related benefits

    33,615



    30,105

    Accrued expenses and other current liabilities

    41,165



    56,648

    Deferred revenue

    20,658



    13,150

    Operating lease liabilities

    9,286



    11,521

    Total current liabilities

    117,633



    127,162

    Operating lease liabilities, noncurrent

    73,327



    83,849

    Deferred revenue, noncurrent

    12,513



    8,814

    Other noncurrent liabilities

    5,029



    4,275

    Total liabilities

    208,502



    224,100

    Commitments and contingencies







    Stockholders' equity:







    Preferred stock, $0.00001 par value; 100,000,000 shares authorized, no shares issued or

    outstanding as of December 31, 2024 and December 31, 2023

    —



    —

    Common stock, $0.00001 par value; 1,100,000,000 shares authorized and 122,291,837

    and 119,095,362 shares issued and outstanding as of December 31, 2024 and 2023

    2



    2

    Additional paid-in capital

    2,177,672



    2,025,890

    Accumulated deficit

    (1,467,047)



    (1,284,420)

    Accumulated other comprehensive loss

    (493)



    (429)

    Total stockholders' equity

    710,134



    741,043

    Total liabilities and stockholders' equity

    $         918,636



    $         965,143

     

    Cumulative instruments sold





    As of December 31,



    2024



    2023



    2022

    Chromium



    5,808



    5,180



    4,411

    Visium CytAssist



    810



    531



    211

    Xenium



    421



    255



    8

    Cumulative instruments sold



    7,039



    5,966



    4,630



    Total consumables reactions sold





    Year ended December 31,



    2024



    2023



    2022

    Chromium



    310,900



    312,500



    290,900

    Visium



    35,400



    29,300



    28,300

    Xenium



    10,800



    5,200



    100

    Total consumable reactions



    357,100



    347,000



    319,300

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/10x-genomics-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-outlook-for-2025-302375081.html

    SOURCE 10x Genomics, Inc.

    Get the next $TXG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TXG

    DatePrice TargetRatingAnalyst
    2/13/2025$25.00 → $12.00Outperform → Market Perform
    Leerink Partners
    9/3/2024$35.00Outperform
    Leerink Partners
    7/22/2024$24.00Hold → Buy
    Jefferies
    7/18/2024$40.00 → $20.00Overweight → Neutral
    JP Morgan
    7/10/2024$55.00 → $25.00Buy → Hold
    Deutsche Bank
    6/27/2024Outperform → Peer Perform
    Wolfe Research
    6/25/2024Buy → Neutral
    Guggenheim
    6/3/2024$24.00Hold
    Jefferies
    More analyst ratings

    $TXG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Participate in the BofA Securities 2025 Healthcare Conference

      PLEASANTON, Calif., April 30, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today that members of its management team will participate in a fireside chat at the BofA Securities 2025 Healthcare Conference on Tuesday, May 13, at 11:20 a.m. Pacific Time. Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company's website at: https://investors.10xgenomics.com/. The webcast will be archived and available for replay for at least 30 days after the event. About 10x Genomics

      4/30/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

      PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      4/14/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Saxonov Serge was granted 171,428 shares, increasing direct ownership by 19% to 1,092,968 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:35:44 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Officer Hindson Benjamin J. was granted 120,535 shares, increasing direct ownership by 36% to 455,859 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:35:12 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Chief Financial Officer Taich Adam was granted 335,632 shares (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      3/19/25 5:34:38 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Mateo Alan bought $445,572 worth of shares (40,000 units at $11.14), increasing direct ownership by 184% to 61,691 units (SEC Form 4)

      4 - 10x Genomics, Inc. (0001770787) (Issuer)

      2/25/25 5:22:04 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by 10x Genomics Inc.

      SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

      11/8/24 2:46:37 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G filed by 10x Genomics Inc.

      SC 13G - 10x Genomics, Inc. (0001770787) (Subject)

      11/5/24 6:07:26 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by 10x Genomics Inc.

      SC 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      10/4/24 2:14:32 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Financials

    Live finance-specific insights

    See more
    • 10x Genomics Reports First Quarter 2025 Financial Results

      PLEASANTON, Calif., May 8, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2025. Recent Updates Revenue was $154.9 million for the first quarter. Excluding $16.8 million related to a patent litigation settlement, revenue was $138.1 million, a 2% decrease from the corresponding period of 2024, primarily driven by a significant decrease in instrument revenue.Ended the first quarter with cash and cash equivalents and marketable securities of $426.9 million. As

      5/8/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics to Report First Quarter 2025 Financial Results on May 8, 2025

      PLEASANTON, Calif., April 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced it will report financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 8, 2025. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.

      4/14/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Outlook for 2025

      PLEASANTON, Calif., Feb. 12, 2025 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided outlook for 2025. Recent Updates Revenue was $165.0 million for the fourth quarter and $610.8 million for the full year of 2024, representing 10% and 1% decreases over the corresponding periods of 2023.In collaboration with the Chan Zuckerberg Initiative (CZI) and Ultima Genomics, launched the Billion Cells Project, an effort to generate an unpre

      2/12/25 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • 10x Genomics downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded 10x Genomics from Outperform to Market Perform and set a new price target of $12.00 from $25.00 previously

      2/13/25 7:11:34 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Leerink Partners initiated coverage on 10x Genomics with a new price target

      Leerink Partners initiated coverage of 10x Genomics with a rating of Outperform and set a new price target of $35.00

      9/3/24 8:15:17 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • 10x Genomics upgraded by Jefferies with a new price target

      Jefferies upgraded 10x Genomics from Hold to Buy and set a new price target of $24.00

      7/22/24 8:21:12 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    Leadership Updates

    Live Leadership Updates

    See more
    • 10x Genomics Announces Senior Leadership Changes

      PLEASANTON, Calif., Aug. 8, 2024 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), a leader in single cell and spatial biology, announced today several changes to its executive team. Mennah Moustafa has been named Chief Commercial Officer, effective August 1. In this role, Moustafa will be responsible for driving commercial strategy and execution and leading the company's sales, support and marketing functions.Justin McAnear, Chief Financial Officer, will resign from the company effective August 30, to join a private company.Adam Taich has been appointed Chief Financial Officer

      8/8/24 4:05:00 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Fanatics Announces Appointment of Lydia Jett and Jonathan Mildenhall to Board of Directors

      Jett and Mildenhall will bring transformative vision and wide-ranging expertise to the fast-growing digital sports platform Separately, Fanatics releases its first environmental, social and governance (ESG) report Fanatics, a leading global digital sports platform, today announced the appointment of preeminent fintech, e-commerce and marketing executives Lydia Jett and Jonathan Mildenhall to its board of directors. Jett, Managing Partner and Head of Global eCommerce and US Consumer Internet Sector Investments at SoftBank Investment Advisers (SBIA), and Mildenhall, co-founder and Executive Chairman of TwentyFirstCenturyBrand and former CMO of Airbnb, bring decades of experience advising an

      5/5/22 8:30:00 AM ET
      $CPNG
      $GH
      $OZON
      $TXG
      Catalog/Specialty Distribution
      Consumer Discretionary
      Medical Specialities
      Health Care
    • ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer

      Dr. Suliman brings over 25 years of drug development, deal-making and company building expertise as ReCode continues advancing its pipeline of novel genetic medicines using its powerful selective organ targeting (SORT) LNP delivery platform ReCode Therapeutics (the "Company"), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Shehnaaz Suliman, M.D., MBA, M.Phil., as chief executive officer and as a member of the board of directors effective today. Former CEO, David Lockhart, Ph.D., will transition to the role of chief scientific officer and will remain president and a member of the boar

      1/10/22 8:00:00 AM ET
      $RARE
      $TXG
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TXG
    SEC Filings

    See more
    • 10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

      8-K - 10x Genomics, Inc. (0001770787) (Filer)

      5/8/25 4:05:10 PM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

      SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      5/7/25 10:55:48 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.

      SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)

      5/7/25 10:40:41 AM ET
      $TXG
      Biotechnology: Laboratory Analytical Instruments
      Industrials